Loading...
Please wait, while we are loading the content...
Similar Documents
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
| Content Provider | MDPI |
|---|---|
| Author | Lucia, Mad’Arová Carmen, Muñoz-Almagro Anna, Skoczyńska Bennett, Julia Hetrich, Marissa Quesada, Maria Garcia Sinkevitch, Jenna Knoll, Maria Deloria Feikin, Daniel Zeger, Scott Kagucia, Eunice Cohen, Adam Ampofo, Krow Brandileone, Maria-Cristina Bruden, Dana Camilli, Romina Castilla, Jesús Chan, Guanhao Cook, Heather Cornick, Jennifer Dagan, Ron Dalby, Tine Danis, Kostas de Miguel, Sara Wals, Philippe De Desmet, Stefanie Georgakopoulou, Theano Gilkison, Charlotte Grgic-Vitek, Marta Hammitt, Laura Hilty, Markus Ho, Pak-Leung Jayasinghe, Sanjay Kellner, James Kleynhans, Jackie Knol, Mirjam Kozakova, Jana Kristinsson, Karl Ladhani, Shamez Donald, Laura Mac Mackenzie, Grant McGeer, Allison Mereckiene, Jolita Morfeldt, Eva Mungun, Tuya Nuorti, J. Paragi, Metka Pilishvili, Tamara Puentes, Rodrigo Saha, Samir Khan, Aalisha Sahu Savrasova, Larisa Scott, J. Suga, Shigeru van der Linden, Mark Verani, Jennifer von Gottberg, Anne Winje, Brita Yildirim, Inci Zerouali, Khalid Hayford, Kyla |
| Copyright Year | 2021 |
| Description | Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3 + 0 schedule constrains generalizability and data from these settings are needed. |
| Starting Page | 696 |
| e-ISSN | 20762607 |
| DOI | 10.3390/microorganisms9040696 |
| Journal | Microorganisms |
| Issue Number | 4 |
| Volume Number | 9 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-03-27 |
| Access Restriction | Open |
| Subject Keyword | Microorganisms Infectious Diseases Invasive Pneumococcal Disease Pneumococcal Conjugate Vaccines Serotypes Vaccine Impact |
| Content Type | Text |
| Resource Type | Article |
